Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    November 2018
  1. YI SW, Choi JS
    Reply to Risk factors for hepatocellular carcinoma.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31801.
    PubMed     Text format    


  2. LAI SW
    Risk factors for hepatocellular carcinoma.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31802.
    PubMed     Text format    


    August 2018
  3. YANG B, Liu JB, So SK, Han SS, et al
    Disparities in Hepatocellular Carcinoma Incidence by Race/Ethnicity and Geographic Area in California: Implications for Prevention.
    Cancer. 2018 Aug 16. doi: 10.1002/cncr.31598.
    PubMed     Text format     Abstract available


    April 2018
  4. YI SW, Choi JS, Yi JJ, Lee YH, et al
    Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31406.
    PubMed     Text format     Abstract available


  5. ERSTAD DJ, Fuchs BC, Tanabe KK
    Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy.
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31257.
    PubMed     Text format     Abstract available


  6. CHINO F, Stephens SJ, Choi SS, Marin D, et al
    The role of external beam radiotherapy in the treatment of hepatocellular cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31334.
    PubMed     Text format     Abstract available


  7. KIM NG, Nguyen PP, Dang H, Kumari R, et al
    Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31373.
    PubMed     Text format     Abstract available


    March 2018
  8. COSTENTIN CE, Mourad A, Lahmek P, Causse X, et al
    Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
    Cancer. 2018 Mar 28. doi: 10.1002/cncr.31215.
    PubMed     Text format     Abstract available


  9. ZHAI XF, Liu XL, Shen F, Fan J, et al
    Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.30915.
    PubMed     Text format     Abstract available


    February 2018
  10. KIM HS, Shaib WL, Zhang C, Nagaraju GP, et al
    Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31192.
    PubMed     Text format     Abstract available


    January 2018
  11. NEUWIRTH MG, Bierema C, Sinnamon AJ, Fraker DL, et al
    Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?
    Cancer. 2018;124:125-135.
    PubMed     Text format     Abstract available


    December 2017
  12. MOMIN BR, Pinheiro PS, Carreira H, Li C, et al
    Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5059-5078.
    PubMed     Text format     Abstract available


    October 2017
  13. MOKDAD AA, Murphy CC, Pruitt SL, Mansour JC, et al
    Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31066.
    PubMed     Text format     Abstract available


    August 2017
  14. TRAN CAO HS, Zhang Q, Sada YH, Chai C, et al
    The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
    Cancer. 2017 Aug 25. doi: 10.1002/cncr.30968.
    PubMed     Text format     Abstract available


  15. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


  16. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available


    July 2017
  17. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


    June 2017
  18. KASUYA G, Kato H, Yasuda S, Tsuji H, et al
    Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30816.
    PubMed     Text format     Abstract available


  19. LIN YY, Yu MW, Lin SM, Lee SD, et al
    Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30851.
    PubMed     Text format     Abstract available


  20. PARIKH ND, Singal AG, Hutton DW
    Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30863.
    PubMed     Text format     Abstract available


  21. CHAN SL, Yeo W, Mo F, Chan AWH, et al
    A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30825.
    PubMed     Text format     Abstract available


  22. KIM Y, Lee SJ, Lee JY, Lee SH, et al
    Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Cancer. 2017;123:1958-1964.
    PubMed     Text format     Abstract available


    May 2017
  23. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available


    April 2017
  24. ZHOU H, Guo M, Gong Y
    Challenge of FNA diagnosis of angiomyolipoma: A study of 33 cases.
    Cancer. 2017;125:257-266.
    PubMed     Text format     Abstract available


    February 2017
  25. HUANG J, Fogg M, Wirth LJ, Daley H, et al
    Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30541.
    PubMed     Text format     Abstract available


  26. FRANKEL TL, Vakiani E, Nathan H, DeMatteo RP, et al
    Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Cancer. 2017;123:568-575.
    PubMed     Text format     Abstract available


  27. SAHLMANN CO, Homayounfar K, Niessner M, Dyczkowski J, et al
    Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Cancer. 2017;123:638-649.
    PubMed     Text format     Abstract available


  28. REDDY SK, Boland PM, Nurkin SJ
    Primary tumor resection does not improve survival among patients with unresectable colorectal cancer metastases-But who determines resectability?
    Cancer. 2017 Feb 8. doi: 10.1002/cncr.30595.
    PubMed     Text format    


    January 2017
  29. PRINTZ C
    Cancer mortality rates vary among specific Asian American ethnic groups.
    Cancer. 2017;123:11.
    PubMed     Text format    


    September 2016
  30. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


    August 2016
  31. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


    July 2016
  32. CRANE CH, Koay EJ
    Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.
    Cancer. 2016;122:1974-86.
    PubMed     Text format     Abstract available


    June 2016
  33. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: